Reina Bianca Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Reina Bianca Tan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Adam J. Small
Adult Congenital Heart Disease Program, Leon H Charney Division of Cardiology, NYU Grossman School of Medicine, New York, NY (A.J.S., D.G.H.).
1 shared publication Anica Bulic
University of Toronto, The Hospital for Sick Children, Labatt Family Heart Centre, 555 University Avenue, Room 1725, Toronto, Ontario M5G1X8, Canada
1 shared publication- Dan G. Halpern
Division of Adult Congenital Heart Disease, Department of Cardiovascular Medicine, NYU Langone Health, New York, USA
1 shared publication Elizabeth A. Stephenson
University of Toronto, The Hospital for Sick Children, Labatt Family Heart Centre, 555 University Avenue, Room 1725, Toronto, Ontario M5G1X8, Canada
1 shared publicationFrank Cecchin
Division of Pediatric Cardiology Department of Pediatrics NYU Grossman School of Medicine New York New York USA
1 shared publication- Matthew Dai
Medicine NYU Grossman School of Medicine, 530 First Ave, HCC 5, New York, NY 10016, USA
1 shared publication
Latest Publications
- 23 September 2025
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 17 (4)
Complex Arrhythmias in Pediatrics and Congenital Heart Disease: Case Review
- 23 September 2025
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 17 (4)
Complex Arrhythmias in Pediatrics and Congenital Heart Disease: Case Review
- 6 September 2025
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 17 (4) , 645-650
Cardiac Channelopathies in the Pediatric Patient
- 6 September 2025
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 17 (4) , 645-650
Cardiac Channelopathies in the Pediatric Patient
- Open Access
- 24 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (15) , 4314
Updates in Arrhythmia Management in Adult Congenital Heart Disease
Arrhythmias are highly prevalent in adults with congenital heart disease. For the clinician caring for this population, an understanding of pathophysiology, diagnosis, and management of arrhythmia is essential. Herein we review the latest updates in diagnostics and treatment of tachyarrhythmias and bradyarrhythmias, all in the context of congenital anatomy, hemodynamics, and standard invasive palliations for congenital heart disease.
- 24 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (15) , 4314
Open AccessUpdates in Arrhythmia Management in Adult Congenital Heart Disease
Arrhythmias are highly prevalent in adults with congenital heart disease. For the clinician caring for this population, an understanding of pathophysiology, diagnosis, and management of arrhythmia is essential. Herein we review the latest updates in diagnostics and treatment of tachyarrhythmias and bradyarrhythmias, all in the context of congenital anatomy, hemodynamics, and standard invasive palliations for congenital heart disease.
- 19 January 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (3) , 365-372
Thromboembolism prophylaxis practices of pediatric and congenital electrophysiologists during invasive electrophysiology studies: A PACES survey
Background: Thromboembolic events related to invasive electrophysiology studies, while rare, can have devastating consequences. Use of systemic anticoagulation for a pediatric or adult-congenital invasive electrophysiology study is recommended, however there is no established standard of practice in this population.Objective: To report on procedural practices for thromboembolism prophylaxis during invasive electrophysiology studies for pediatric patients and adults with congenital heart disease.Methods: An anonymous web-based survey was sent to the members of the Pediatric and Congenital Electrophysiology Society. The survey focused on pre-procedural, intra-procedural, and post-procedural thromboembolism prophylaxis practices during invasive electrophysiology studies. Significant practice variation was defined as <90% concordance among respondents.Results: Survey was completed by 73 members; 52 (71%) practicing in the United States, 65 (89%) practicing in an academic institution, and 14 (19%) in an institution that performs more than 200 invasive electrophysiology procedures annually. Responses showed significant variation in practice. Prior to an invasive electrophysiology procedure, 25% discontinue aspirin while 47% discontinue anticoagulants. Heparin is given for all procedures by 32%. When heparin is administered, the first dose is given by 32% after sheaths are placed, 42% after crossing into the systemic atrium, and 26% just prior to systemic-side ablation. Most target an activated clotting time between 200-300 seconds. Post systemic-side ablation, 58% do not initiate a heparin infusion. Post-procedural oral agents were initiated on day of procedure by 34% of respondents and on post-procedure day 1 by 53%. If treating with aspirin, 74% use low-dose (3-5 mg/kg or 81 mg daily), and 68% treat for 4-6 weeks.Conclusion: There is significant variation in thromboembolism prophylaxis for invasive EP studies among pediatric and congenital electrophysiologists. Further studies are needed to optimize the management of thromboembolism prophylaxis in this population.
- 19 January 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (3) , 365-372
Thromboembolism prophylaxis practices of pediatric and congenital electrophysiologists during invasive electrophysiology studies: A PACES survey
Background: Thromboembolic events related to invasive electrophysiology studies, while rare, can have devastating consequences. Use of systemic anticoagulation for a pediatric or adult-congenital invasive electrophysiology study is recommended, however there is no established standard of practice in this population.Objective: To report on procedural practices for thromboembolism prophylaxis during invasive electrophysiology studies for pediatric patients and adults with congenital heart disease.Methods: An anonymous web-based survey was sent to the members of the Pediatric and Congenital Electrophysiology Society. The survey focused on pre-procedural, intra-procedural, and post-procedural thromboembolism prophylaxis practices during invasive electrophysiology studies. Significant practice variation was defined as <90% concordance among respondents.Results: Survey was completed by 73 members; 52 (71%) practicing in the United States, 65 (89%) practicing in an academic institution, and 14 (19%) in an institution that performs more than 200 invasive electrophysiology procedures annually. Responses showed significant variation in practice. Prior to an invasive electrophysiology procedure, 25% discontinue aspirin while 47% discontinue anticoagulants. Heparin is given for all procedures by 32%. When heparin is administered, the first dose is given by 32% after sheaths are placed, 42% after crossing into the systemic atrium, and 26% just prior to systemic-side ablation. Most target an activated clotting time between 200-300 seconds. Post systemic-side ablation, 58% do not initiate a heparin infusion. Post-procedural oral agents were initiated on day of procedure by 34% of respondents and on post-procedure day 1 by 53%. If treating with aspirin, 74% use low-dose (3-5 mg/kg or 81 mg daily), and 68% treat for 4-6 weeks.Conclusion: There is significant variation in thromboembolism prophylaxis for invasive EP studies among pediatric and congenital electrophysiologists. Further studies are needed to optimize the management of thromboembolism prophylaxis in this population.
- 30 August 2023
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 15 (4) , 467-480
Epicardial Devices in Pediatrics and Congenital Heart Disease
- 30 August 2023
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 15 (4) , 467-480
Epicardial Devices in Pediatrics and Congenital Heart Disease